KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $3.4 billion.

  • Moderna's Short-term Investments fell 3543.94% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 3543.94%. This contributed to the annual value of $5.1 billion for FY2024, which is 1051.43% down from last year.
  • As of Q3 2025, Moderna's Short-term Investments stood at $3.4 billion, which was down 3543.94% from $3.9 billion recorded in Q2 2025.
  • Over the past 5 years, Moderna's Short-term Investments peaked at $6.7 billion during Q4 2022, and registered a low of $2.3 billion during Q1 2021.
  • Over the past 5 years, Moderna's median Short-term Investments value was $5.0 billion (recorded in 2022), while the average stood at $4.7 billion.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 17760.93% in 2021, then tumbled by 3590.68% in 2025.
  • Moderna's Short-term Investments (Quarter) stood at $3.9 billion in 2021, then skyrocketed by 72.65% to $6.7 billion in 2022, then fell by 14.93% to $5.7 billion in 2023, then dropped by 10.51% to $5.1 billion in 2024, then plummeted by 33.86% to $3.4 billion in 2025.
  • Its last three reported values are $3.4 billion in Q3 2025, $3.9 billion for Q2 2025, and $4.4 billion during Q1 2025.